A newly announced clinical trial aims to evaluate the effectiveness and safety of linaprazan glurate in maintaining healing for patients with healed erosive esophagitis (EE) caused by gastroesophageal reflux disease (GERD). Cinclus Pharma Holding AB is spearheading this research, emphasizing its commitment to improving GERD treatment options. The trial has not yet begun recruitment but highlights a new step towards innovative therapeutic solutions.
Published: January 12, 2026
In this article:
- What is being studied?
- How does this impact GERD treatment?
- Clinical trial design
- FAQs
- Conclusion
- Disclaimer
- Announcement details
What is being studied?
The upcoming trial will analyze the clinical performance of two dosing regimens of linaprazan glurate—the investigational drug—against lansoprazole, an already approved and widely utilized proton pump inhibitor (PPI). This research will specifically focus on the drug’s role in maintaining healing for patients with healed erosive esophagitis caused by GERD.
Both high and low doses of linaprazan glurate will be evaluated, ensuring coverage of a wide therapeutic range. The comparator, lansoprazole, reflects the current medical standard and will allow researchers to benchmark the investigational drug’s efficacy and safety accurately.
How does this impact GERD treatment?
GERD is a pervasive condition impacting millions globally, often managed with PPIs like lansoprazole. However, some individuals continue to experience symptoms or complications, highlighting the need for alternative approaches. Linaprazan glurate represents a novel therapeutic candidate that may address unmet needs by providing a different mechanism of action or safety profile compared to existing treatments.
If successful, this trial could pave the way for expanded options in GERD management, especially for patients who exhibit inadequate response or tolerance issues with conventional therapies.
Clinical trial design
This study, sponsored by Cinclus Pharma Holding AB, will rigorously evaluate the potential of linaprazan glurate to maintain healing in GERD patients. The trial details include:
- Conditions studied: Gastroesophageal reflux disease (GERD) and healed erosive esophagitis.
- Interventions: Two experimental doses of linaprazan glurate (high and low) and one comparator dose of lansoprazole.
- Sponsor: Cinclus Pharma Holding AB.
- Recruitment status: Not yet recruiting.
Details on enrollment, trial locations, and primary endpoints will be available once recruitment begins. Participants’ safety and treatment efficacy will remain the core focus throughout the trial.
FAQs
- What is linaprazan glurate?
Linaprazan glurate is an investigational drug being evaluated for its ability to maintain healing in GERD-related erosive esophagitis. - What is the purpose of this trial?
The trial compares linaprazan glurate with lansoprazole to assess efficacy and safety in patients with healed erosive esophagitis. - Who is conducting this trial?
The sponsor for this study is Cinclus Pharma Holding AB, a company specializing in gastroenterological conditions. - When will recruitment start?
As of publication, recruitment has not begun. Updates will be shared once enrollment opens.
Conclusion
This clinical trial marks a significant step toward developing new GERD treatments. Cinclus Pharma Holding AB is exploring linaprazan glurate as a potential alternative or complement to existing therapies. With GERD management remaining a global challenge, the outcome of this research could drive meaningful advancements and help address unmet therapeutic needs.
Disclaimer
This article is intended for professionals in the clinical, regulatory, and quality assurance fields. It is informational only and does not constitute legal or medical advice.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07313774?term=medical+device